No Data
No Data
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Institutional Owners May Be Pleased With Recent Gains After 85% Loss Over the Past Year
Applied Materials, Amcor, RLX Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Morgan Stanley Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $2.5
Piper Sandler Reaffirms Their Hold Rating on Pacific Biosciences (PACB)